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Genetical and environmental factors play an interactive role in the 
development  of  acute  and  chronic  leukemias.HLA  antigens  have  been 
considered as  possible  genetic risk  factors.The  aim  of this  work was to 
investigate a possible association between HLA class II polymorphisms and 
leukemias  and  myelodysplastic  syndrome.In  the  present  study  we 
investigated  HLA  class  II  antigens,DR/DQ  and  DR51/DR52/DR53 
haplotypes  in  100  patients:7  suffering  from  myelodysplastic  syndrome 
(MDS),37 from acute lymphoblastic leukemia(ALL),32 from acute myeloid 
leukemia (AML) and 24 from chronic myeloid leukemia(CML).A panel of 
210  healthy  unrelated  individuals  of  the  same  origin,  from  Vojvodina, 362                                                                                   GENETIKA, Vol. 43, No. 2, 361-370, 2011 
served  as  controls.HLA  phenotyping  was  performed  by  two  color 
fluorescence method. In patients suffering from MDS was found a positive 
association  with  DR7(RR=2.598,EF=0.175)  and  DQ7(3)(RR=4.419, 
EF=0.632), while negative association was found for DR15(2)(RR=0.405, 
PF=0.172)  and  DQ6(1)  (RR=0.889,  PF=0,936).Positive  association  was 
found in the group of patients with ALL for DR7(RR=2.391,EF=0.688) and 
DQ2(RR=1.62,  EF=0.15),while  negative  association  was  found  with 
DQ5(1)(RR=0.075,  PF=0.324).In  the  group  of  patients  with  AML,there 
were  positive  associations  with  DR11(5)(RR=1.732,EF=0.211),DQ2(RR= 
1.594,  EF=0.151)  and  DQ7(3)  (RR=2.547,EF=0.266),while  possible 
protective  antigen  was  DQ5(1)  (RR=0.107,RF=0.701).Higher  RR  than  1 
and  EF>0.15,  in  patients  suffering  from  CML  was  found  for 
DQ6(1)(RR=1.661,EF=0.232),  while  negative  association  was  found  for 
DR4 (RR=0.182,PF=0.155).Possible protective haplotype in this study was 
DR3DQ8(3)  for  patients  suffering  from  AML(RR=0.007,  PF=0.501).The 
distribution  of  DR53-DR53  haplotypes  showed  significant  difference  in 
male patients with ALL(6% vs 0.09%), while DR52-DR52 haplotype was 
significantly less frequent in male patients with CML (4% vs 20.47%) and 
female patients with MDS (1% vs 18.57%), respectively, in comparison to 
controls. We deduced that DR7 antigen in male patients with ALL has the 
greatest impact to the higher frequency of DR53-DR53 haplotype in this 
type of leukemia.The role of HLA antigens as risk factors for development 
of  leukemias  in  our  population  was  shown  and  furthermore  it  could  be 
useful in clinical practice. 
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INTRODUCTION 
The  association  between  human  leukocyte  antigens  (HLA)  and  various 
hematological malignancies has been  studied extensivly. The involvement of the 
HLA system has also been examined in leukemias following the demonstration of a 
major histocompatibility complex (MHC) influence on the development of mause 
leukemia (VOJVODIĆ, 2008).In 1964, Lilly and coworkers, reported an increased risk 
of spontaneous and virus-induced leukemia in congenic mice homozygous for the H-
2
k haplotype. Human studies in leukemias point to an association with HLA-A2, 
HLA-B12 in all types of leukemias as well as with HLA-A9, -A11, -A25, -A32, -B7, 
-B21, -Cw3 and -Cw4 in acute lymphoblastic leukemia (ALL) and acute myeloid 
leukemia (AML) (VOJVODIĆ et al.,2001, BARION, et al.,2007). Despite the excessive 
number of serological studies on the HLA-DR locus, it was not shown the consistent 
association  with  leukemias.  The  only  observed  HLA-DR/DQ  association  was 
regarded  to  male-specific  homozygosity  for  the  HLA  class  II  supertype  DR53 
(DORAK et al.,2002a, DORAK et al.,2002b). There are three HLA class II supertypes: 
HLA-DR51,-DR52 and -DR53 encoded by DRB3, DRB4 and DRB5 genes. HLA-
DR53 is an HLA class II supertypic antigen expressed at somewhat lower level than 
the private HLA-DR antigens (MOHANAPRIYA et al.,2010). The supertypic specificity S.VOJVODIC et al. HLA ANTIGENS AND SUSCEPTIBILITY OF LEUKEMIAS                      363 
HLA-DR53 is encoded by HLA-DRB4 locus in the HLA class II region. HLA-DRB4 
is one of the expressed HLA loci, which exists only on haplotypes possessing HLA-
DRB1*04,  DRB1*07  and  DRB1*09.  DRB3  gene  is  present  on  HLA-DRB1*03, 
DRB1*11,  DRB1*12,  DRB1*13  and  DRB1*14  haplotypes,  while  DRB5  gene  is 
present  on  HLA-DRB1*15  and  DRB1*16  haplotypes.  The  remaining  haplotypes 
DRB1*01, DRB1*08 and DRB1*10, constitute a small fraction that do not belong to 
any of supertypic groups (DORAK et al.,2002a). The HLA-DRB4 gene or its protein 
product HLA-DR53 have been associated with increased risk for all major types of 
leukemias (MACHULA et al.,2001). The aim of the present study was to investigate 
the possible association of HLA class II antigens and haplotypes with leukemias and 
myelodysplastic sindrome (MDS) in the population of Vojvodina.  
 
MATERIALS AND METHODS 
One hundred patients from Vojvodina (51 females, 49 males) were included 
in  study.  They  were  divided  into  four  subgroups  according  to  the  type  of 
leukemia/disease: 24 suffering from chronic myeloid leukemia (CML) (8 males, 16 
females),7 suffering from MDS (4 males, 3 females), 32 suffering from AML (16 
males, 16 females) and 37 suffering from ALL (21 males, 16 females).Control group 
consisted of 210 healthy individuals who resided in the same geographic area. The 
HLA-DR  and  -DQ  loci  antigens  were  identified  by  the  two  color  fluorescence 
method (VARTDAL et al.,1986). Since some haplotypes lack supertypical locus, the 
presence of supertypic haplotypes partly relies on the results of HLA DR typing. 
DR52  antigen  is  present  on  HLA-DR3,  -DR11(5),  -DR12(5),  -DR13(6)  and  -
DR14(6) haplotypes; DR-53 on HLA-DR4, -DR7 and -DR9 haplotypes; DR51 on 
HLA-DR15(2) and -DR16(2) haplotypes. HLA-DR1, -DR8 and -DR10 haplotypes 
do not belong to any of these lineages. A sample was assigned as homozygous for 
HLA-DR53 lineage when no other supertype was detected or having a double dose 
of DR53 family (HLA-DR4,-DR7 and -DR9). A sample was assigned as HLA-DR52 
homozygote (having double dose of DR52 family (HLA-DR3, -DR11(5), -DR12(5), 
-DR13(6) and -DR14(6)). Those typed as having only HLA-DR15(2) or -DR16 (2), 
were  assigned  as  DR51  homozygote.Phenotype  and  haplotype  frequencies  were 
calculated by direct counting method, using following formula: A= n/N, where n is 
number  of persons with  given antigen and N is total number  of persons studied 
(SHEN et al.,2008). Student′s t test was used for comparisons of HLA-DR51/52/53 
haplotype  frequencies  between  subgroups  of  patients  and  controls.  Relative  risk 
(RR) for measuring strenght of association with each antigen and haplotype was 
calculated by the method of WOOLF (ARMITAGE et al., 2002), according to following 
formula:    
P x C
C x P RR
− +
− +
= ,where 
Ρ
+ = is the number of patients who have a given antigen;C
- = is the number of healthy 
persons who do not have a given antigen;Ρ
-= is the number of patients who do not 
have  a  given  antigen;C
+   =  is  the  number  of  healthy  persons  who  have  a  given 
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When  RR was  higher  than 1, we calculated the etiologic fraction, while for  RR 
values less than 1, we calculated the preventive fraction. The etiologic fraction (EF) 
or population atrributable risk, that gives the proportion of disease, due to the HLA 
marker associated with disease, was calculated according to method of Green, using 
following formula: 
) 1 (
) (
FAP
FAP FAD
EF
−
−
= ,  
where FAD is the frequency of given HLA antigen in the subgroup of patients and 
FAP is the frequency of HLA antigen in controls. The preventive fraction (PF), that 
gives  the percentage of cases that can be prevented if a population is exposed to an 
intervention,  compared  to  an  unexposed  population,  was  calculated  according  to 
following formula: 
f f RRx
xf RR
FP
+ −
−
=
) 1 (
) 1 (
,  
where RR is relative risk and f is the frequency of HLA antigen in the subgroup of 
patients  (GREEN  et  al.,1982).  The  association  was  considered  positive  if  the 
calculated EFs were higher than 0.15 and negative if calculated PFs were more than 
0.15.  The  Pearson  χ
2  goodness-of-fit  test  was  used  to  valuate  Hardy-Weinberg 
genetic equilibrium for phenotypic data (ARMITAGE et al., 2002). 
 
RESULTS 
The  distribution  of  HLA-DR  and  -DQ  loci  specificities  in  patients  with 
leukemias and MDS and in controls, is shown in Table 1. All of the HLA loci in 
patients and controls were consistent with Hardy-Weinberg equilibrium. The results 
showing  positive  or  negative  associations  are  ilustrated  in  Table  2.  Our  results 
demonstrated  that  there  were  several  HLA  class  II  antigens  associated  with  an 
increased  risk  of  developing  leukemias  and  MDS,  such  as:  DR6(1)  in  CML 
(RR=1.661,  EF=0.232),  DR11(5)  and  DQ7(3)  in  AML  (RR=1.732,  EF=0.211; 
RR=2.547, EF= 0.266), respectively, DR7 and DQ2 in ALL (RR=2.391,EF=0.688; 
RR=1.62,EF=0.15),  respectively,  and  DR7  and  DQ7(3)  in  MDS 
(RR=2.598,EF=0.175; RR=4.419,EF=0.632), respectively. On the other hand, five 
antigens were associated with reduced risk of developing leukemias and MDS. The 
frequency  of  DR4  in  CML  (RR=0.182,PF=0.155),  DQ5(1)  in  AML  (RR=0.107, 
PF=0.701), DQ5(1)  in ALL  (RR=0.075,  PF=0.324)  and  DR15(2)  and  DQ6(1) in 
MDS  (RR=0.405,  PF=  0,172;  RR=0.889,  PF=0.936),  respectively,  antigens  were 
decreased in investigated subgroups of patients. 
The  distribution  of  supertypical  haplotypes  in  patients  and  controls  is 
presented  in  Table  3.  There  was  a  difference  in  the  distribution  of  haplotypes 
between male and female patients. The greatest impact to the difference came from 
two supertypical haplotypes: increased homozygosity for HLA-DR53 in male ALL 
patients  and  decreased  homozygosity  for  HLA-DR52  in  male  CML  patients,  in 
comparison to the control group (t=2.043; t=105.984), respectively. 
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Table 1. The distribution of HLA class II antigens in patients with leukemias and MDS and in 
controls 
  Patients 
Antigen  MDS n=7  ALL n=37  AML n=32  CML n=24  Total 
n=100 
Controls 
n=210 
DR1  0.285  0.243  0.156  0.208  0.210  0.171 
DR3  0.142  0.216  0.312  0.125  0.230  0.195 
DR4  0  0.216  0.125  0.041  0.130  0.190 
DR11(5)  0.285  0.297  0.500  0.416  0.390  0.366 
DR12(5)  0  0.027  0.031  0  0.020  0.004 
DR13(6)  0.142  0.189  0.125  0.250  0.190  0.166 
DR14(6)  0.142  0.054  0.031  0.041  0.050  0.080 
DR7  0.285  0.270  0.093  0.208  0.190  0.133 
DR8  0.142  0  0.031  0.041  0.030  0.038 
DR9  0  0.027  0  0  0.010  0.009 
DR10  0  0  0  0.083  0.020  0.023 
DR15(2)  0.142  0.243  0.312  0.291  0.280  0.290 
DR16(2)  0.142  0.081  0.156  0.041  0.100  0.066 
Blank  0.285  0.135  0.187  0.250  0.190  0.261 
DQ5(1)  0.428  0.351  0.281  0.333  0.333  0.785 
DQ6(1)  0.428  0.405  0.468  0.583  0.480  0.457 
DQ2  0.285  0.405  0.406  0.291  0.370  0.300 
DQ7(3)  0.714  0.324  0.531  0.416  0.440  0.361 
DQ8(3)  0  0.108  0.093  0.041  0.080  0.152 
DQ9(3)  0  0  0  0  0  0.009 
DQ4  0  0  0.031  0.041  0.020  0.033 
Blank  0.142  0.378  0.250  0.250  0.290  0.376 
 
 
DISCUSSION 
This is the first HLA class II association study in leukemias and MDS in the 
population  of  Vojvodina.  The  distribution  of  HLA  class  II  antigens  in  patients 
suffering from leukemias and MDS in comparison to controls, showed the increase 
in frequency of DQ6(1)(40.5%), DQ2 (40.5%), DQ7(3) (32.4%) and DR7 (27%) in 
ALL patients. The most common HLA class II antigens in AML and CML patients 
were DQ7(3) (53.1%), (41.6%) respectively, DR11(5) (50%), (41.6%) respectively, 
and  DQ6(1)  (46.8%),  (58.3%)  respectively,  as  well  as  DQ7(3)  (71.4%),  DQ6(1) 
(42.8%)  and  DQ5(1)  (42.8%)  in  MDS  patients  (Table  1).  The  analysis  of 
susceptibility with HLA class II antigens with leukemias and MDS showed that RR 
to develop ALL is 2.391 in patients having DR7, which is in accordance with study 
of Von Fliedner and coworkers (DORAK,2008) and that RR to develop AML is 1.732 
for patients having DR11(5) (Table 2).  
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Table 2. Disease susceptibility with HLA class II antigens  
Antigen  MDS  ALL  AML  CML 
  RR  EF  PF  RR  EF  PF  RR  EF  PF  RR  EF  PF 
DR1  1.932  0.137  -  1.556  0.086  -  0.900  -  0.017  1.273  0.044  - 
DR3  0.683  -  0.160
*  1.137  0.026  -  1.872  0.145  -  0.589  -  0.080 
DR4  -  -  -  1.174  0.032  -  0.609  -  0.074  0.182  -  0.155
* 
DR11(5)  0.690  -  0.113  0.744  -  0.092  1.732  0.211
*  -  1.233  0.078  - 
DR12(5)  -  -  -  5.801  0.022  -  6.688  0.026  -  -  -  - 
DR13(6)  0.831  -  0.043  1.170  0.016  -  0.717  -  0.047  1.674  0.100  - 
DR14(6)  1.903  0.065  -  0.656  -  0.027  0.367  -  0.050  0.491  -  0.041 
DR7  2.598  0.175
*  -  2.391  0.688
*  -  0.668  -  0.044  1.712  0.086  - 
DR8  4.190  0.108  -  -  -  -  0.809  -  0.006  1.082  0.003  - 
DR9  -  -  -  2.887  0.075  -  -  -  -  -  -  - 
DR10  -  -  -  -  -  -  -  -  -  4.053  0.060  - 
DR15(2)  0.405  -  0.172
*  0.785  -  0.062  1.110  0.030  -  1.004  0.001  - 
DR16(2)  2.342  0.081  -  1.247  0.016  -  2.615  0.096  -  0.605  -  0.026 
DQ5(1)  0.748  -  0.143  0.075  -  0.324
*  0.107  -  0.701
*  0.136  -  0.675 
DQ6(1)  0.889  -  0.936
*  0.808  -  0.087  0.953  -  0.022  1.661  0.232
*  - 
DQ2  0.930  -  0.021  1.620  0.150
*  -  1.594  0.151
*  -  0.957  -  0.012 
DQ7(3)  4.419  0.632
*  -  0.848  -  0.049  2.547  0.266
*  -  1.260  0.086  - 
DQ8(3)  -  -  -  0.675  -  0.049  0.572  -  0.065  0.240  -  0.129 
DQ4  -  -  -  -  -  -  0.937  -  0.002  1.252  0.009  - 
NEA=negative association (PF>0.15) PA=positive association(EF>0.15) 
 
 
Table 3. Supertypical haplotypes (%) in patients and controls and t test values 
MDS  ALL  AML  CML  Controls 
males  females  males  females  males  females  males  females 
Supertypical 
haplotypes 
%  t test  %  t test  %  t test  %  t test  %  t test  %  t test  %  t test  %  t test 
male 
% 
female 
% 
DR52-DR52  2  5.91  1  13.41  6  3.94  3  3.98  7  3.55  8  3.70  4  105.9  4  4.37  20.47  18.57 
DR52-DR53  1  2.67  0  4.83  2  2.38  8  0.58  3  1.58  2  3.20  2  1.92  2  3.19  6.19  10 
DR52-DR51  0  4.68  0  4.01  4  2.66  1  3.00  3  2.46  3  1.78  2  3.04  4  1.18  9.52  7.14 
DR53-DR53  1  0.03  0  4.01  6  2.04  2  2.27  0  1.41  0  4.01  0  1.41  1  3.00  0.95  7.14 
DR53-DR51  0  2.68  0  2.26  0  2.68  0  2.26  1  1.46  0  2.26  0  2.68  1  0.95  3.33  2.38 
DR51-DR51  0  3.80  1  2.11  3  1.34  2  1.35  2  1.92  3  0.77  0  3.72  1  2.11  6.19  4.76 
Other 
haplotypes* 
0  2.01  1  0.32  0  2.01  0  1.71  0  2.01  0  1.73  0  2.01  3  0.83  1.90  1.42 
*-haplotypes lacking an HLA class II supertype 
V=307, border value=1.97 
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Our study revealed positive associatin between DQ6(1) antigen and CML 
which is also reported by MUNDHADA and coworkers (MUNDHADA et al.,2004),but 
was not consistent to the findings of AMIRZARGAR and coworkers (AMIRZARGAR et 
al.,2007),  who  reported  negative  association  of  DQ6(1)  in  CML  patients.  In  our 
population, HLA-DR4 (RR=0.182, PF=0.155) antigen was shown to have negative 
association with CML. The only significant positive association with AML against 
control  group  was  HLA-DR11(5)  (RR=1.732),  which  is  also  reported  by 
SARAFNEJAD  and  coworkers  (SARAFNEJAD  et  al.,2006),and  DQ7(3)  (RR=2.547). 
HLA-DQ5(1) antigen was found in lower frequency in AML patients in comparison 
to controls (RR=0.107, PF=0.701), suggesting to be a protective factor against AML. 
In our study, there were two HLA class II antigens in positive and three in negative 
association  with  MDS.  Positive  association  was  found  with  DR7  (RR=2.598, 
EF=0.175)  and  DQ7(3)  (RR=  4.419,  EF=0.632),  while  negative  association  was 
observed  with  DR3  (RR=0.683,  PF=0.16),  DR15(2)  (RR=  0,405,  PF=0.172)  and 
DQ6(1)  (RR=0.889,  PF=0.936).  Our  findings  regarding  positive  association  with 
MDS patients do not correspond with an earlier reports, since, as SAUNTHARARAJAH 
and coworkers (SAUNTHARARAJAH et al.,2002), and XIAO and coworkers (XIAO et 
al.,2009) reported, HLA-DR15(2) was shown as genetic susceptibility marker for 
developing MDS. In our population, any positive association between HLA class II 
haplotypes and leukemias and MDS, was not found. On the other hand, the only 
negative  association  was  found  between  HLA-DR3DQ8(3)  haplotype  and  AML, 
suggesting to possible protective role of this haplotype against AML. This study 
provided  evidence  for  HLA  class  II  supertypical  haplotypes  role  in  developing 
leukemias and MDS. The main finding was different gender specific frequency of 
supertypical  HLA-DR53  homozygous  haplotype  in  male  ALL  patients  in 
comparison to controls (6% vs 0.9%, t=2.043). HLA-DR53 associated susceptibility 
to ALL in male specific manner was also described in the previous studies (DORAK et 
al.,2002a,  DORAK  et  al.,2002b).Significant  difference in  HLA-DR53  homozygous 
haplotype was observed for ALL females in comparison to controls (2% vs 7.1%, 
t=2.274), but with protective role, in contrast to male ALL patients.  
An association between HLA antigens and diseases may be attributable to 
either  direct  effect  of  the  marker  antigen  or  to  another  antigen  in  linkage 
disequilibrium with it. The analysis of HLA-DR antigens belonging to HLA-DR53 
supertypic group, showed the strong susceptibility of HLA-DR7 antigen in the group 
of ALL patients, due to its higher frequency (RR=2.391, EF=0.688) in comparison to 
controls. Other HLA-DR antigens belonging to DR53 supertypical lineage (HLA-
DR4  and  -DR9)  were  present  with  increased  frequency  in  ALL  patients  in 
comparison to controls, but with no positive association, due to lower EFs than 0.15 
(EF=0.032,  EF=0.075),  respectively  (Table  2).  Therefore,  we  considered  them 
having no impact on DR53 supertype susceptibility to develop ALL, in contrast to 
HLA-DR7 antigen.  
Our study showed the protective role of homozygous HLA-DR52 haplotype 
in other investigated diseases: CML (t for male group=105.98, t for female group 
4.37), MDS (t for male group=5.91, t for female group 13.41), AML (t for male 368                                                                                   GENETIKA, Vol. 43, No. 2, 361-370, 2011 
group=3.55, t for female group 3.70) and ALL (t for male group=3.94, t for female 
group 3.98) (Table 3). These results are consistent to the previous studies reporting 
the protective role of HLA-DR52 supertype family in other leukemias (DORAK et al., 
2002a,  DORAK  et  al.,  2002b).  The  protective  role  of  other  combination  of 
supertypical haplotypes was shown in our study for some of investigated diseases but 
not for all diseases at the same time, in contrast to HLA-DR52 haplotype.   
 
CONCLUSION 
The results of present study suggest that homozygosity for HLA-DR53 is a 
genetic  risk  factor  for  development  of ALL  in  males.  The  positive  and  negative 
associations between HLA class II antigens and haplotypes and leukemias and MDS 
was shown in population of Vojvodina, and furthermore the results of our study 
could be useful in clinical practice. 
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I z v o d 
Uslovi spoljne sredine i genetski faktori imaju uzajamnu ulogu u razvoju 
akutnih  i  hroničnih  leukemija.  HLA  antigeni  se  smatraju  mogućim  genetskim 
faktorom rizika. Clij ovog rada je utvrđivanje moguće udruženosti polimorfizama II 
HLA  klase  i  leukemija  i  mijelodisplaznog  sindroma.  U  ovoj  studiji  ispitivana  je 
distribucija  HLA antigena II klase, DR/DQ i DR51/DR52/DR53 haplotipova u 100 
bolesnika:  7  koji  boluju  od  mijelodisplaznog  sindroma  (MDS),  37  od  akutne 
limfoblastne leukemje (ALL), 32 od akutne mijeloblastne leukemije (AML) i 24 od 
hronične mijeloidne leukemije (CML). Grupa od 210 zdravih nesrodnih osoba sa 
teritorije  Vojvodine,  čini  kontrolnu  grupu.  HLA  fenotipizacija  je  vršena 
dvokolornom  fluorescentnom  metodom.  U  svim  isptivanim  grupama  leukemija  i 
MDS  uočene su  pozitivne i  negativne  udruženosti sa II klasom HLA antigena u 
populaciji  Vojvodine. Moguć zaštitni haplotip  u  ovoj studiji  je DR3DQ8(3),  kod 
bolesnika  koji  boluju  od  AML  (RR=0.007,  PF=0.501).  Distribucija  DR53-DR53 
supertipskog haplotipa je pokazala značajnu razliku u muških bolesnika sa ALL (6% 
vs 0.09%), dok je frekvencija DR52-DR52 haplotipa značajno niža u svim grupama 
obolelih u odnosu na kontrolnu.  Prema rezultatima studije izveden je zaključak da 
DR7 antigen  u muških bolesnika  sa ALL ima najveći efekat na  višu frekvenciju 
DR53-DR53  haplotipa  u  ovom  tipu  leukemije.  Uloga  HLA  antigena  kao  faktora 
rizika u nastanku leukemija u našoj populaciji je pokazana a rezultati ove studije 
mogu biti upotrebljena u kliničkoj praksi. 
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